DOCSLIB.ORG

Pharmacology October 1995 Number 1 and Experimental Therapeutics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacology October 1995 Number 1 and Experimental Therapeutics TheJournalof VOLUME275 PHARMACOLOGY OCTOBER 1995 NUMBER 1 AND EXPERIMENTAL THERAPEUTICS Contents ANALGESIA AND DRUGS OF ABUSE Tiapride Attenuates Pain Transmission Through an Indirect Nobuaki Takeshita, Yoshitaka Ohkubo and 23 Activation of Central Serotonergic Mechanism Isamu Yamaguchi Characterization of the Spinal Antinociceptive Activity of Tony L. Yaksh, Annika B. Malmberg, 63 Constrained Peptidomimetic Oploids Seonggu Ro, Peter Schiller and Murray Goodman Spinal Opioid Receptors and Adenosine Release: Catherine M. Cahill, Thomas D. White and 84 Downloaded from Neurochemical and Behavioral Characterization of Opioid Jana Sawynok Subtypes Felbamate Relieves Several Abnormal Pain Sensations in Rats Yoshiki Imamura and Gary J. Bennett 177 with an Experimental Peripheral Neuropathy Intrathecal Baclofen and Muscimol, But Not Midazolam, are David M. Ding and Tony L. Yaksh 219 Antinociceptive Using the Rat-Fonnalin Model jpet.aspetjournals.org Opioid Modulation of Fetal Glucose Homeostasis: Role of Hazel H. Szeto, Yi Soong, Dun-li Wu and 334 Receptor Subtypes Peter Y. Cheng Microinfusion of Mu but Not Delta or Kappa Opioid Agonists Fred J. Helmstetter, 381 into the Basolateral Amygdala Results in Inhibition of the Tail Patrick S. F. Beilgowan and Flick Reflex in Pentobarbital-Anesthetized Rats Laura H. Poore Distribution of Morphine 6-Glucuronide and Morphine Across Tor A. Aasmundstad, J#{248}rgM#{248}rlandand 435 at ASPET Journals on September 25, 2021 the Blood-Brain Barrier in Awake, Freely Moving Rats Ragnhild E. Paulsen Investigated by in Vivo Microdialysis Sampling Distribution of the g.t and 8 Opioid Binding Sites in the Brain Jean-Pascal de Wade, Kalervo Kiianmaa 518 of the Alcohol-Preferring AA and Alcohol.Avoiding ANA and Christina Gianoulakis Lines of Rats AUTONOMIC PHARMACOLOGY 5-Hydroxytryptamine-Induced Synovial Plasma Extravasation Pamela A. Pierce, Guo-Xi Xie, 502 Is Mediated via 5-Hydroxytryptamine2A Receptors on Stephen J. Peroutka, Paul G. Green and Sympathetic Eflerent Terminals Jon D. Levine BEHAVIORAL PHARMACOLOGY Antagonism of the Discriminative Stimulus Effects of t- Jenny L. Wiley, John A. Lowe, 1 Tetrahydrocannabinol in Rats and Rhesus Monkeys Robert L. Baister and Billy R. Martin Effects of Single and Multiple Intravenous Cocaine Injections Richard W. Foltin, Ingrid Chnstiansen, 38 in Humans Maintained on Methadone Frances R. Levin and Marian W. Fischman Noradrenergic Involvement in the Discriminative Stimulus Roger D. Spealman 53 Effects of Cocaine in Squirrel Monkeys Development of Behavioral Sensitization to Cocaine: Influence Christian A. Heidbreder, 150 of Kappa Opioid Receptor Agonists Dusica Babovic-Vuksanovic, Mohammed Shoaib and Toni S. Shippenberg Schedule-Controlled Behavioral Effects of the Selective 2- Mark J. Benvenga, Paul L. Ornstein and 164 Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid J. David Leander Antagonist LY293558 in Pigeons Drug Discrimination Analysis of Midazolam under a Three- Chrisne A. Sannerud and Nancy A. Ator 183 Lever Procedure II: Differential Effects of Benzodiazepine Receptor Agonists Cocaine Sensitization in Periadolescent and Adult Rats Giovanni Laviola, Robin D. Wood, 345 Cynthia Kuhn, Reynolds Francis and Linda P. Spear Contents continued on ii Contents continued from i Agonist and Antagonist Effects of Dynorphin A-(1-13) in a Eduardo R. Butelman, Charles P. France 374 Thermal Anlinociception Assay in Rhesus Monkeys and James H. Woods Comparison of Benzodiazepine Receptor LigandS with Partial J. R. Martin, F. Jenck and J.-L. Moreau 405 Agonistic, Antagonistic or Partial Inverse Agonistic Properties in Precipitating Withdrawal in Squirrel Monkeys CARDIOVASCULAR PHARMACOLOGY Interactions between Hydroxocobalamin and Nitric Oxide Lori G. Rochelle, Salvatore J. Morana, 48 (NO): Evidence for a Redox Reaction between NO and Harriet Kruszyna, Michael A. Russell, Reduced Cobalainin and Reversible NO Binding to Oxidized Dean E. Wilcox and Roger P. Smith Cobalamin Zatebradine, a Specific Bradycardic Agent, Alters the Paul S. Pagel, Christopher P. Harkin, 127 Hemodynamic and Left Ventricular Mechanical Actions of Douglas A. Hettrick and David C. Warltier Levosimendan, a New Myofflament aIcium Sensitizer, in Conscious Dogs Pharmacological Characterization of the Selective Nonpeptide Henri N. Doods, Wolfgang Wienen, 136 Neuropeptide Y Yl Receptor Antagonist BIBP 3226 Michael Entzeroth, Klaus Rudolf, Downloaded from Wolfgang Eberlein, Wolfhard Engel and Heike A. Wieland Subtype Selectivity and Antagonistic Profile of the Nonpeptide Heike A. Wieland, Klaus D. Willim, 143 Yl Receptor Antagonist BIBP 3226 Michael Entzeroth, Wolfgang Wienen, Klaus Rudolf, Wolfgang Eberlein, Wolfhard Engel and Henri N. Doods jpet.aspetjournals.org Quantification of the In Vivo Potency of the Adenosine A2 Ron A. A. Math#{244}t, 245 Receptor Antagonist S-(3..Chlorostyryl)Caffeine Josy M. Gubbens-Stibbe, Willem Soudijn, Kenneth A. Jacobson, Adriaan P. IJzerman and Meindert Danhof Changes in Sympathetic Neurotransmission and Adrenergic Annalisa Rubino and Geoffrey Burnstock 422 Control of Cardiac Contractility During 1,3-Dipropyl-8- Sulfophenyixanthine-Induced Hypertension at ASPET Journals on September 25, 2021 CELLULAR AND MOLECULAR PHARMACOLOGY Modulation by o Ligands of Intracellular Free Ca Teruo Hayashi, Ariyuki Kagaya, 207 Mobilization by N#{149}Methyl..D.aspartate In Primary Culture of Minoru Takebayashi, Masami Shimizu, Rat Frontal Cortical Neurons Yosuke Uchitomi, Nobutaka Motohashi and Shigeto Yamawaki The Endothelin Receptor Profile in L6 Myotubes Zoltan Fekete, Xiao Yan Yang, 215 Masayuki Kimura and Abraham Aviv Acute Amiodarone Terminates Ventricular Fibrillation by Shoji Kojima, Shao T. Wu, 254 Modifying Cellular Ca9 Homeostasis in Isolated Perfused Joan Wikman-Coffelt and Rat Hearts William W. Parmley Actions of the Benzopyran Compound Terikalant on James G. McLarnon and Rending Xu 389 Macroscopic Currents In Rat Ventricular Myocytes Prevention and Reduction of Neural Damage in Ischemic George C. Y. Chiou and Show-Jen Hong 474 Strokes by w4N,N’-Diethylamlno)-n-alkyl-3,4,5- Trimethoxybenzoate Compounds CHEMOTHERAPY/GENE THERAPY Cepharanthin, a Multidrug Resistant Modifier, is a Substrate Midori Hirai, Kumiko Tanaka, 73 for P-Glycoprotein Takako Shimizu, Yusuke Tanigawara, Masato Yasuhara, Ryohei Hori, Yoshiyuki Kakehi, Osamu Yoshida, Kazumitsu Ueda, Tohru Komano and Ken-Ichi Inui Induction of Apoptosis in Murine and Human Neuroblastoma Theresa L. Hartsell, Jack C. Yalowich, 479 Cell Lines by the Enedlyne Natuii4 Product Neocarzinostatin Mary K. Ritke, A. J. Martinez and Nina Felice Schor DRUG METABOLISM AND DISPQITION Phenethyl Isothiocyanate, a Ne Dietary Liver Aldehyde Kai 0. Lindros, Thomas Badger, 79 Dehydrogenase Inhibitor Martin Ronis, Magnus Ingelman-Sundberg and Martti Koivusalo Contents continued on iii Contents continued from ii Hepatic Transport of Rose Bengal by Perfused Rabbit Liver: B. A. Luxon and P. D. King 296 The Effect of Albumin Binding on the Unidirectional Rate Constants In Vitro Pharmacokinetics of Phosphorothioate Antisense Rosanne M. Crooke, Mark J. Graham, 462 Margaret E. Cooke and Stanley T. Crooke Oligonucleotides ENDOCRINE PHARMACOLOGY Prophylaxis of Genetically Determined Diabetes by Diazoxide: Toni Aizawa, Nahoko Taguchi, 194 A Study In a Rat Model of Naturally Occurring Obese Yoshihiko Sato, Tetsuo Nakabayashi, Diabetes Hideko Kobuchi, Hiroya Hidaka, Takeshi Nagasawa, Fujiki Ishihara, Nobuo Itoh and Kiyoshi Hashizume GASTROINTESTINAL PHARMACOLOGY Role of Na in the Asymmetric Paracellular Transport of 4- Wan-Ching Yen and Vincent H. L. Lee 114 Phenylazobenzyloxycarbonyl-L-Pro-L-Leu-Gly.L-Pro-D-Arg Across Rabbit Colonic Segments and Caco-2 Cell Monolayers Downloaded from Characterization of Endothelln Receptors Mediating Graham H. Allcock, Bruno Battistini, 120 Mechanical Responses to the Endothelins In the IsOlated Alain Fournier, Timothy D. Warner and Stomach Strip of the Rat John R. Vane Peptide Structural Requirements for Antagonism Differ Jaw-Town Un, David H. Coy, 285 between the Two Mammalian Bombesin Receptor Subtypes Samuel A. Mantey and Robert T. Jensen Arachidonic Acid Cascade and Stimulation of Acetylchollne Shun-ichi Mameya, TakafUmi Sawa and 319 jpet.aspetjournals.org Release by Human Recombinant Interleukln-1 in Guinea Pig Kohtaro Taniyama ileum Preventive Effect of Rebainipide on Gastric Lesions Induced Chi Dae Kim and Ki Whan Hong 340 by Ischemla-Reperfusion In the Rat Necessity of Newly Synthesized AlP by Creatine Kinase for Tadayoshi Takeuchi, Akikazu Fujita, 429 Contraction of Permeabilized LOngitUdInal Muscle Toshiaki Ishii, Hideaki Nishio and Preparations of Rat Proximal Colon Fumiaki Hata at ASPET Journals on September 25, 2021 Reversal of Cyclosporine A-Induced Alterations In Bifiary Emilio Fern#{225}ndez,Ma I. Gal#{225}n, 442 Secretion by S.Adenosyl-L-Methionine in Rats Dominica Moran, Jos#{233}M.Gonz#{225}lez-Buitrago, Maria E. Mufloz and Rafael Jim#{233}nez Different Molecular Forms of Basic Fibroblast Growth Factor Stefano Kusstatscher, Zsuzsa Sandor, 456 (bFGF) Accelerate Duodenal Ulcer Healing In Rats Sandor Szabo, Andrew Seddon and Peter BOhien Peripheral and Central Cholecystokinin Receptors Regulate A. Rodrlguez-Membrilla, V. Martinez and 486 Postprandlal Intestinal Motility In the Rat P. Vergara Roles of Prostaglandins, Nitric Oxide and the Capsalcin- Mine Kinoshita, Eisuke Kume and 494 Sensitive Sensory Nerves In Gastroprotection Produced by Hajime Tamaki Ecabet Sodium IMMUNOPHARMACOLOGY New Antlinflammatory
Load more

Recommended publications
  • Wachter-Et-Al-LSM-32(2003)101-110.Pdf
    Lasers in Surgery and Medicine 32:101–110 (2003) Topical Rose Bengal: Pre-Clinical Evaluation of Pharmacokinetics and Safety 1 1 1 1 2 Eric Wachter, PhD, * Craig Dees, PhD, Jay Harkins, Timothy Scott, PhD, Mark Petersen, DVM, 3 4 Rusty E. Rush, MS, and Amy Cada, PhD 1Provectus Pharmaceuticals, Inc., Knoxville, Tennessee 37931 2College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee 37916 3Springborn Laboratories, Inc., Spencerville, Ohio 45887 4Therimmune Research Corporation, Gaithersburg, Maryland 20879 Background and Objectives: Rose bengal (RB) is a should have minimal potential for side effects, such as potent photosensitizer that has largely been overlooked as a prolonged photosensitivity. potential photodynamic therapy (PDT) agent. In this study, Since RB readily photobleaches [29], its photodynamic the feasibility of topical delivery of RB to the epidermis has effects may be self-limiting. This is particularly relevant for been evaluated. treatment of many dermatologic conditions, such as psoria- Study Design/Materials and Methods: Topical formu- sis and actinic keratosis, since precise light dosimetry is lations of RB were assessed on murine and rabbit skin for impractical over the large surface areas typically involved pharmacokinetic properties, cutaneous toxicity, and photo- in these diseases: a PDT regimen that exhibits self-limiting sensitization. effects would avoid the need for complex light dosimetry. Results: Hydrophilic formulations (1% RB) exhibited The combination of photodynamic potential, substantial
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al
    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
    [Show full text]
  • Ophthalmic Herpes Zoster
    OPHTHALMIC HERPES ZOSTER RONALD J. MARSH and MATTHEW COOPER London SUMMARY Fig. 1 shows the age and sex distribution, which is A current review of ophthalmic zoster is presented biased in favour of females and compares with 50.7% including its virology, immunology, epidemiology and males, 49.3% females in another series.5 The 1981 census pathogenesis. We give our findings in 1356 patients for Greater London recorded 48% males and 52% referred to the Zoster Clinic at Moorfields Ey e Hospital, females. London. The treatment of the disease and its ocular com­ ONSET plications is discussed. There is a prodromal influenza-like illness of varying Ophthalmic herpes zoster is a disease varying in severity duration, with headache, pyrexia, malaise, depression, and from devastating, threatening life and sight, to so mild that sometimes neck stiffness, which may last up to a week it may pass unnoticed. The ophthalmic division of the fifth before the rash appears. This is shortly followed by local­ cranial nerve is affected in 7-17.5% of herpes zoster ised pain over the distribution of the ophthalmic nerve, patients. 1-5 Ocular involvement complicates approxi­ lymph node swelling in the corresponding drainage areas mately 50% of these cases and very rarely cases of maxil­ and, occasionally, a red eye. The localised pain is well lary herpes zoster,l affecting many of the tissues of the known to precede the rash by several days in some cases. globe and orbit by highly varied types of lesions. This probably represents the replication and migration We felt it would be helpful to report our experience with phase of the disease and is possibly accompanied by a lim­ the disease because the large number of cases we have ited viraemia.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Corneal Wound Repair After Rose Bengal and Green Light Crosslinking: Clinical and Histologic Study
    Cornea Corneal Wound Repair After Rose Bengal and Green Light Crosslinking: Clinical and Histologic Study Patricia Gallego-Munoz,˜ 1 Luc´ıa Ibares-Fr´ıas,1 Elvira Lorenzo,1 Susana Marcos,2 Pablo Perez-Merino,´ 2 Nandor Bekesi,2 Irene E. Kochevar,3 and M. Carmen Mart´ınez-Garc´ıa1 1Departamento de Biolog´ıa Celular, Histolog´ıa y Farmacolog´ıa, GIR de Tecnicas´ Opticas´ para el Diagnostico,´ Universidad de Valladolid, Valladolid, Spain 2Instituto de Optica,´ Consejo Superior de Investigaciones Cient´ıficas, Madrid, Spain 3Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States Correspondence: M. Carmen PURPOSE. To evaluate corneal wound healing after treatment with a new collagen crosslinking Mart´ınez-Garc´ıa, Departamento de protocol using rose bengal dye and green light (RGX). Biolog´ıa Celular, Histolog´ıa y Farm- acolog´ıa, Facultad de Medicina, Uni- METHODS. One cornea of 20 New Zealand rabbits was de-epithelialized (DE) in an 8-mm versidad de Valladolid, C/Ramon´ y diameter circle and, in another group (n ¼ 25), the DE corneas were then stained with 0.1% Cajal 7, 47005 Valladolid, Spain; rose bengal for 2 minutes and exposed to green light (532 nm) for 7 minutes (RGX). The mariacarmen.martinez.garcia@ contralateral eyes without treatment acted as controls. The animals were clinically followed uva.es. including fluorescein staining and pachymetry. Healing events were analyzed after euthanasia 0 Submitted: December 23, 2016 at 2, 30, and 60 days. Cell death (TUNEL assay), cell proliferation (5-bromo-2 -deoxyuridine Accepted: June 1, 2017 incorporation), and cell differentiation to myofibroblasts (a-SMA labeling) were carried out.
    [Show full text]
  • PF 44(1) Table of Contents Publish Date: November 1, 2017
    PF 44(1) Table of Contents Publish date: November 1, 2017 PROPOSED IRA: Proposed Interim Revision Announcements USP MONOGRAPHS IN-PROCESS REVISION: In-Process Revision GENERAL NOTICES FOR USP-NF General Notices to USP-NF (USP42-NF37) 1. TITLE AND REVISION 2. OFFICIAL STATUS AND LEGAL RECOGNITION 3. CONFORMANCE TO STANDARDS 4. MONOGRAPHS AND GENERAL CHAPTERS 5. MONOGRAPH COMPONENTS 6. TESTING PRACTICES AND PROCEDURES 7. TEST RESULTS 8. TERMS AND DEFINITIONS 9. PRESCRIBING AND DISPENSING 10. PRESERVATION, PACKAGING, STORAGE, AND LABELING GENERAL CHAPTERS <7> LABELING (USP42-NF37) <561> ARTICLES OF BOTANICAL ORIGIN (USP42-NF37) <1057> BIOTECHNOLOGY-DERIVED ARTICLES—TOTAL PROTEIN ASSAY (USP42-NF37) <1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE (USP42-NF37) <1176> PRESCRIPTION BALANCES AND VOLUMETRIC APPARATUS USED IN COMPOUNDING (USP42- NF37) REAGENTS, INDICATORS, AND SOLUTIONS Reagent Specifications Aflatoxin B1 [NEW] (USP42-NF37) Aflatoxin B2 [NEW] (USP42-NF37) Aflatoxin G1 [NEW] (USP42-NF37) Aflatoxin G2 [NEW] (USP42-NF37) Clozapine N-Oxide [NEW] (USP42-NF37) Deuterated Ethanol [NEW] (USP42-NF37) Deuterium Chloride Solution [NEW] (USP42-NF37) Deuterium Oxide (USP42-NF37) Isobutyl Chloroformate [NEW] (USP42-NF37) PF 4x(x) Table of Contents 1 | P a g e Polyethylene Glycol 400 [NEW] (USP42-NF37) Polyethylene Glycol 4000 [NEW] (USP42-NF37) Pyridine, Anhydrous [NEW] (USP42-NF37) Trifluoroacetic Acid Ethyl Ester [NEW] (USP42-NF37) Test Solutions Citric Acid TS [NEW] (USP42-NF37) Sodium Chloride TS [NEW] (USP42-NF37) Volumetric Solutions
    [Show full text]
  • Curable Composition and Skin Adhesive
    (19) TZZ ¥Z¥_T (11) EP 2 957 303 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.12.2015 Bulletin 2015/52 A61L 15/58 (2006.01) A61L 24/04 (2006.01) C08K 5/10 (2006.01) C09J 167/06 (2006.01) (2006.01) (21) Application number: 14173247.9 C08L 67/06 (22) Date of filing: 20.06.2014 (84) Designated Contracting States: (72) Inventor: Schüwer, Nicolas AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 1010 Lausanne (CH) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoffmann Eitle Designated Extension States: Patent- und Rechtsanwälte PartmbB BA ME Arabellastraße 30 81925 München (DE) (71) Applicant: NITTO DENKO CORPORATION Osaka 567 (JP) (54) Curable composition and skin adhesive (57) The present invention pertains to compositions The composition of the invention may be cross- linked to containing a polycondensate and optionally an oil com- yield an adhesive composition. The composition of the ponent, wherein the polycondensate is derived from a invention and the adhesive composition of the invention dicarboxylic acid component, a diol component and an may be used on substrates such as tapes and patches ethylenically unsaturated dicarboxylic acid component. in the medical field. EP 2 957 303 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 957 303 A1 Description 1. Technical Field of the Invention 5 [0001] The present invention relates to a curable composition comprising: a polycondensate of a dicarboxylic acid, a diol, and a polymerizable ethylenic derivative; and optionally an oil additive.
    [Show full text]
  • Medications in Pregnant and Nursing Mothers
    Medications in Pregnant and Nursing Mothers NADINE M. GIRGIS, OD, FAAO ASSISTANT PROFESSOR YIN C. TEA, OD, FAAO CHIEF, PEDIATRICS AND BINOCULAR VISION ASSISTANT PROFESSOR Gestation age vs fetal age Gestation age-sperm penetrates the egg and zygote is formed Zygote (fertilized egg) travels from fallopian tube to uterus During this time, egg divides into cells - called a morula Continued dividing and morula - called a blastocyst - embeds in the uterus anywhere from 6-12 days after conception This begins the embryonic stage and fetal age begins Fetal development-1st trimester Gestation age week 3-fetal age week 1: a lot of basic growth Brain, spinal cord, heart, GI tract begin development 1st trimester Gestation age-week 4 and 5: embryo ¼ inch long Arm and leg buds, ears, eyes forming Placenta forming and producing hormones Heart is beating at a steady rhythm Movement of rudimentary blood through blood vessels 1st trimester Gestation age week 6: embryo is ½ in length Lungs, jaw, nose, plate formation, hands and feet Hand and feet buds have webbed structures Brain forming into complex parts 1st trimester Gestation age week 7: weighs less than an aspirin All essential organs have begun to form Hair, nail follicles, eyelids and tongue starting to form Trunk begins to straighten out 1st trimester Gestation age week 8: 1 in long, size of a bean All parts of adult are now present in the embryo Bones beginning to form Muscles begin to contract Facial features, including eyelids more developed Gestation age weeks 9-13: 3 in and weighs
    [Show full text]
  • Waste Disposal Guide
    Waste Disposal Guide How to Properly Dispose of Waste Materials Generated at Michigan State University Environmental Health & Safety (EHS) / Office of Radiation, Chemical & Biological Safety (ORCBS) C124 Research Complex‐Engineering East Lansing, MI 48824‐1326 Revised April 2009 CONTACT INFORMATION Campus Emergency: 911 ORCBS Phone Number: (517) 355-0153 ORCBS Fax Number: (517) 353-4871 ORCBS E-mail Address: [email protected] ORCBS Web Address: http://www.orcbs.msu.edu TABLE OF CONTENTS Sections Introduction ................................................................................................................... 4 Hazardous Waste Defined ............................................................................................ 5 Requirements for Chemical Waste ............................................................................... 6 Classification of Chemical Waste .................................................................................. 7 Containers ..................................................................................................................... 8 Container Label ............................................................................................................. 9 General Labeling & Packaging Procedures .................................................................. 9 Specific Labeling & Packaging Procedures ............................................................. 9-15 Scheduling a Chemical Waste Pick-up ......................................................................
    [Show full text]
  • Inhibition of Vesicular Glutamate Storage and Exocytotic Release by Rose Bengal
    Journal of Neurochemistry, 2001, 77,34±42 Inhibition of vesicular glutamate storage and exocytotic release by Rose Bengal Kiyokazu Ogita,*,1 Koji Hirata,* David G. Bole,* Sumiko Yoshida,*,2 Yutaka Tamura,*,3 Anne Marie Leckenby* and Tetsufumi Ueda*,²,³ *Mental Health Research Institute, Departments of ²Pharmacology and ³Psychiatry, Medical School, The University of Michigan, Ann Arbor, Michigan, USA Abstract the synaptosome result in a corresponding decrease in the It had been thought that quantal size in synaptic transmission amount of [3H]Glu released in a depolarization- (induced by 4- is invariable. Evidence has been emerging, however, that aminopyridine) and Ca21-dependent manner. In contrast, quantal size can be varied under certain conditions. We ¯uorescein, the halogen-free analog of Rose Bengal, which is 3 3 present evidence that alteration in vesicular [ H]L-glutamate devoid of inhibitory activity on vesicular [ H]Glu uptake, failed to (Glu) content within the synaptosome (a pinched-off nerve change the amount of exocytotically released [3H]Glu. These ending preparation) leads to a change in the amount of observations suggest that glutamate synaptic transmission exocytotically released [3H]Glu. We found that Rose Bengal, a could be altered by pharmacological intervention of glutamate polyhalogenated ¯uorescein derivative, is a quite potent uptake into synaptic vesicles in the nerve terminal, a new membrane-permeant inhibitor (K 19 nM) of glutamate mode of synaptic manipulation for glutamate transmission. i uptake into isolated synaptic vesicles. This vesicular Glu Keywords: glutamate, inhibitor, release, Rose Bengal, uptake inhibition was achieved largely without affecting H1- vesicular uptake. pump ATPase. We show that various degrees of reduction J.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 2020 Aetna Standard Plan
    Plan for your best health Aetna Standard Plan Aetna.com Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna). Aetna Pharmacy Management refers to an internal business unit of Aetna Health Management, LLC. Aetna Pharmacy Management administers, but does not offer, insure or otherwise underwrite the prescription drug benefits portion of your health plan and has no financial responsibility therefor. 2020 Pharmacy Drug Guide - Aetna Standard Plan Table of Contents INFORMATIONAL SECTION..................................................................................................................6 *ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS* - DRUGS FOR THE NERVOUS SYSTEM.................................................................................................................................16 *ALLERGENIC EXTRACTS/BIOLOGICALS MISC* - BIOLOGICAL AGENTS...............................18 *ALTERNATIVE MEDICINES* - VITAMINS AND MINERALS....................................................... 19 *AMEBICIDES* - DRUGS FOR INFECTIONS.....................................................................................19 *AMINOGLYCOSIDES* - DRUGS FOR INFECTIONS.......................................................................19 *ANALGESICS - ANTI-INFLAMMATORY* - DRUGS FOR PAIN AND FEVER............................19 *ANALGESICS - NONNARCOTIC* - DRUGS FOR PAIN AND FEVER.........................................
    [Show full text]